INTEGRATE study: Treatment pathways, outcomes and resource use in patients with multiple myeloma

Tisagenlecleucel shows no EFS improvement on standard of care in 2L for aggressive B-cell NHL

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM

Latest in combination therapy for NDMM patients

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma